ECSP10010725A - Inhibidores de ciclopropil-polimerasa - Google Patents

Inhibidores de ciclopropil-polimerasa

Info

Publication number
ECSP10010725A
ECSP10010725A EC2010010725A ECSP10010725A ECSP10010725A EC SP10010725 A ECSP10010725 A EC SP10010725A EC 2010010725 A EC2010010725 A EC 2010010725A EC SP10010725 A ECSP10010725 A EC SP10010725A EC SP10010725 A ECSP10010725 A EC SP10010725A
Authority
EC
Ecuador
Prior art keywords
hydrogen
alkyl
compounds
cyclopropil
polymerase inhibitors
Prior art date
Application number
EC2010010725A
Other languages
English (en)
Inventor
Pierre Jean-Marie Bernard Raboisson
Tim Hugo Maria Jonckers
Koen Vandyck
Original Assignee
Centocor Ortho Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41095413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010725(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centocor Ortho Biotech Inc filed Critical Centocor Ortho Biotech Inc
Publication of ECSP10010725A publication Critical patent/ECSP10010725A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Los compuestos de fórmula I:donde:R2 es hidrógeno o alquilo C1-C4;R3 y R4 son hidrógeno, -C(=O)R5, o -C(=O)CHR6-NH2; oR3 es hidrógeno y R4 es un éster de monofosfato, difosfato, o trifosfato; oR3 es hidrógeno, -C(=O)CHR5, o -C(=O)CHR6-NH2 y R4 escada R5 es hidrógeno, alquilo C1-C6, o cicloalquilo C3-C7;R6 es hidrógeno o alquilo C1-C6;R7 es fenilo opcionalmente sustituido; naftilo; o indolilo;R8 y R8' son hidrógeno, alquilo C1-C6, bencilo; oR8 y R8' combinados forman cicloalquilo C3-C7;R9 es alquilo C1-C6, bencilo, o fenilo opcionalmente sustituido;siempre que R2, R3 y R4 no sean todos hidrógeno;o su sal o solvato aceptable para uso farmacéutico;formulaciones farmacéuticas con los compuestos I; el uso de compuestos I, incluyendo los compuestos de fórmula I donde R2, R3 y R4 son todos hidrógeno, como inhibidores del VHC.
EC2010010725A 2008-07-01 2010-12-29 Inhibidores de ciclopropil-polimerasa ECSP10010725A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08159396 2008-07-01
EP08171005 2008-12-08

Publications (1)

Publication Number Publication Date
ECSP10010725A true ECSP10010725A (es) 2011-04-29

Family

ID=41095413

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010725A ECSP10010725A (es) 2008-07-01 2010-12-29 Inhibidores de ciclopropil-polimerasa

Country Status (29)

Country Link
US (1) US8431588B2 (es)
EP (1) EP2141172B1 (es)
JP (1) JP5624029B2 (es)
KR (1) KR20110038683A (es)
CN (2) CN102083845B (es)
AP (1) AP2010005505A0 (es)
AR (1) AR072428A1 (es)
AU (1) AU2009266004B2 (es)
BR (1) BRPI0913643A2 (es)
CA (1) CA2729316A1 (es)
CL (1) CL2010001634A1 (es)
CO (1) CO6321255A2 (es)
DK (1) DK2141172T3 (es)
EA (1) EA022754B1 (es)
EC (1) ECSP10010725A (es)
ES (1) ES2396803T3 (es)
HK (1) HK1226080A1 (es)
HR (1) HRP20121068T1 (es)
IL (1) IL209932A (es)
MX (1) MX2010014493A (es)
NI (1) NI201000231A (es)
PL (1) PL2141172T3 (es)
PT (1) PT2141172E (es)
SI (1) SI2141172T1 (es)
SV (1) SV2010003779A (es)
TW (1) TW201012814A (es)
UY (1) UY31950A (es)
WO (1) WO2010000459A1 (es)
ZA (1) ZA201009294B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2736482C (en) * 2008-09-08 2018-01-02 Novomer, Inc. Polycarbonate polyol compositions and methods
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
TW201201815A (en) * 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
CA2822556A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
EA201390988A1 (ru) 2010-12-30 2014-04-30 Энанта Фармасьютикалз, Инк. Фенантридиновые макроциклические ингибиторы сериновой протеазы вируса гепатита c
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
JP5845841B2 (ja) 2011-11-18 2016-01-20 東芝ライテック株式会社 照明制御装置
US8673926B2 (en) 2012-02-14 2014-03-18 University Of Georgia Research Foundation, Inc. Spiro[2.4]heptanes for treatment of flaviviridae infections
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
RU2590952C1 (ru) * 2015-05-26 2016-07-10 Вячеслав Энгельсович Семёнов Средство гепатопротекторного действия
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
WO2018048937A1 (en) 2016-09-07 2018-03-15 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
IL288737B (en) 2017-02-01 2022-09-01 Atea Pharmaceuticals Inc Hemisulfate nucleotide salt for treatment of hepatitis c virus
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
IL308921A (en) 2021-06-17 2024-01-01 Atea Pharmaceuticals Inc Combination anti-HCV therapy is beneficial

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2170020C (en) 1992-12-29 2005-08-02 Dale J. Kempf Retroviral protease inhibiting compounds
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
TW200500375A (en) * 2002-06-28 2005-01-01 Idenix Cayman Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
EA014685B1 (ru) * 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
WO2006021341A1 (en) * 2004-08-23 2006-03-02 F. Hoffmann-La Roche Ag Antiviral 4’-azido-nucleosides
AP2009004812A0 (en) 2006-10-10 2009-04-30 Medivir Ab HCV nucleoside inhibitor

Also Published As

Publication number Publication date
KR20110038683A (ko) 2011-04-14
US8431588B2 (en) 2013-04-30
HK1226080A1 (zh) 2017-09-22
JP2011526270A (ja) 2011-10-06
AU2009266004A1 (en) 2010-01-07
SV2010003779A (es) 2011-02-08
HRP20121068T1 (hr) 2013-01-31
SI2141172T1 (sl) 2013-02-28
WO2010000459A1 (en) 2010-01-07
EA201170118A1 (ru) 2011-06-30
TW201012814A (en) 2010-04-01
MX2010014493A (es) 2011-05-19
IL209932A (en) 2013-12-31
AU2009266004B2 (en) 2014-01-30
CN105693794A (zh) 2016-06-22
CN102083845A (zh) 2011-06-01
ES2396803T3 (es) 2013-02-27
NI201000231A (es) 2011-09-03
CA2729316A1 (en) 2010-01-07
AR072428A1 (es) 2010-08-25
DK2141172T3 (da) 2013-01-21
JP5624029B2 (ja) 2014-11-12
IL209932A0 (en) 2011-02-28
CO6321255A2 (es) 2011-09-20
UY31950A (es) 2010-01-29
EA022754B1 (ru) 2016-02-29
CN102083845B (zh) 2016-09-14
AP2010005505A0 (en) 2010-12-31
PT2141172E (pt) 2013-01-14
CL2010001634A1 (es) 2011-08-05
PL2141172T3 (pl) 2013-03-29
ZA201009294B (en) 2012-06-27
EP2141172B1 (en) 2012-10-24
BRPI0913643A2 (pt) 2015-11-24
EP2141172A1 (en) 2010-01-06
US20110092460A1 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
ECSP10010725A (es) Inhibidores de ciclopropil-polimerasa
UY32308A (es) Nucleótidos uracil ciclopropílicos
CO6440533A2 (es) Nucleósidos espiro oxetánicos uracílicos
ES2486267T3 (es) 2-(Fenil 2-fluoro-substituido)-6-amino-5-cloro-4-pirimidinacarboxilatos y su uso como herbicidas
AR083676A1 (es) Compuestos heterociclicos, útiles como inhibidores de quinasa y composiciones farmaceuticas que los contienen
DOP2010000046A (es) Compuestos de biciclolactama sustituida
PE20130187A1 (es) Bis(difluorometil) pirazoles como fungicidas
CO6210729A2 (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona procedimientos para su preparacion y su uso como agente farmaceutico
CO6290658A2 (es) Derivados de azetidina y ciclobutano como inhibidores de jack
AR087754A1 (es) 6h-tieno[3,2,-f][1,2,4]triazolo[4,3-a][1,4]diazepina
UY30527A1 (es) Tetrazolilos macrociclicos como inhibidores de serina proteasa de hepatitis c
CL2012000999A1 (es) Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina.
ECSP077649A (es) Piridazinonilos macrociclicos como inhibidores de serina proteasa de hepatitis c
AR061238A1 (es) Compuestos de oxilmilo macrociclico inhibidores de proteasa de hepatitis c
AR069435A1 (es) Derivados de aminotiazol, proceso para la obtencion de los mismos, composiciones farmaceuticas y su uso como inhibidores de la fbpasa
UY30391A1 (es) Compuesto de oximilo aciclico inhibidores de proteasa de hepatitis c
AR072803A1 (es) Tetrahidrocinolinas como inhibidores de la 11- beta -hsd1 para la diabetes
AR088414A1 (es) Derivados sustituidos de indol
DOP2012000296A (es) Derivados de 3,4-dihidropirrolo[1,2-a]pirazina-2,8(1h)-dicarboxamida su preparación y su uso terapéutico
AR085542A1 (es) Compuestos de azaespirodecanona como inhibidores de hsl
AR098854A1 (es) 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas
AR098583A1 (es) Compuesto de sulfonamida de benzotiofeno, composición farmacéutica que lo comprende y su uso para la preparación de dicha composición
UY31262A1 (es) Compuestos de biciclolactama sustituida
CU20100017A7 (es) Compuestos de biciclolactama sustituida
AR108805A1 (es) Derivados de pirimidina como inhibidores de lrrk2